A panel of diverse Pseudomonas aeruginosa clinical isolates for research and development

Abstract

Objectives Pseudomonas aeruginosa is a leading cause of community- and hospital-acquired infections. Successful treatment is hampered by its remarkable ability to rapidly develop resistance to antimicrobial agents, primarily through mutation. In response, WHO listed carbapenem-resistant P. aeruginosa as a Priority 1 (Critical) pathogen for research and development of new treatments. A key resource in developing effective countermeasures is access to diverse and clinically relevant strains for testing. Herein we describe a panel of 100 diverse P. aeruginosa strains to support this endeavour. Methods WGS was performed on 3785 P. aeruginosa isolates in our repository. Isolates were cultured from clinical samples collected from healthcare facilities around the world between 2003 and 2017. Core-genome MLST and high-resolution SNP-based phylogenetic analyses were used to select a panel of 100 strains that captured the genetic diversity of this collection. Antibiotic susceptibility testing was also performed using 14 clinically relevant antibiotics. Results This 100-strain diversity panel contained representative strains from 91 different STs, including genetically distinct strains from major epidemic clones ST-111, ST-235, ST-244 and ST-253. Seventy-one distinct antibiotic susceptibility profiles were identified ranging from pan-susceptible to pan-resistant. Known resistance alleles as well as the most prevalent mutations underlying the antibiotic susceptibilities were characterized for all isolates. Conclusions This panel provides a diverse and comprehensive set of P. aeruginosa strains for use in developing solutions to antibiotic resistance. The isolates and available metadata, including genome sequences, are available to industry, academia, federal and other laboratories at no additional cost.

A novel phenolic derivative inhibits AHL-dependent quorum sensing signaling in Pseudomonas aeruginosa

“…Finally, we tested the compound against PA clinical strains isolated from the respiratory tract of patients since it is well known that PAO1, a strain domesticated by extensive use in the laboratory, might produce results far from in vivo conditions for different virulence-related phenotypes ( El-Shaer et al, 2016 ). In accordance with the genetic diversity and phenotypic heterogeneity of P. aeruginosa field strains ( Finnan et al, 2004 ; Lebreton et al, 2021 ; Nassar et al, 2022 ), our clinical isolates significantly differed as regard pyocyanin production and swarming motility (data not shown). Although the clinical strains responded differently to treatment, overall, we reported a significant reduction in the production of pyocyanin, swarming and elastase B in most strains tested ( Figure 6 ).…”

Methylene Blue–Mediated Antimicrobial ​Photodynamic Therapy Against Clinical Isolates of Extensively Drug Resistant ​Gram-Negative Bacteria Causing Nosocomial Infections in Thailand, An In Vitro Study

“…The greatly diverse and exceptionally dynamic genetic composition of the successful opportunistic pathogens primarily contributes virulence and antibiotic resistance. This genomic diversity has been found not only the strains in different clinically relevant infections but also among ones isolated from different geographic locations (Subedi et al, 2018;Galac et al, 2020;Lebreton et al, 2021;Kiyaga et al, 2022).…”

A panel of diverse Klebsiella pneumoniae clinical isolates for research and development

“…This document outlined strategies to combat this threat, including access to diverse isolates for testing. In response to these demands, the US DoD, through the MRSN, has published distinct panels (with corresponding metadata and genomes) for the ESKAPE pathogens A. baumanii [24] and P. aeruginosa [25]. Herein we expand these panels by constructing a novel panel of K. pneumoniae isolates that, to our knowledge, is the only comprehensive panel publicly available for research and development.…”

“…In response to these demands, the US DoD, through the MRSN, has published distinct panels (with corresponding metadata and genomes) for the ESKAPE pathogens A. baumanii [24] and P. aeruginosa [25]. Herein we expand these panels by constructing a novel panel of K.…”

“…pneumoniae maintained by the Multidrug-Resistant Organism Repository and Surveillance network (MRSN) [23] and collected globally between 2001 and 2020. Comparable to our previous work [24, 25], we constructed a reference panel of 100 K . pneumoniae clinical isolates that captures the extensive genetic diversity of this species, as well as variable antibiotic resistance gene content and virulence gene content, along with a wide range of antimicrobial susceptibility profiles.…”